Incidence, risk factors, and clinical significance of Epstein–Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Incidence, risk factors, and clinical significance of Epstein–Barr virus reactivation in myelodysplastic syndrome after allogeneic haematopoietic stem cell transplantation

Published:2019-02-04 Issue:4 Volume:98 Page:987-996
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Wang Hong,Zhang Tong-Tong,Qi Jia-Qian,Chu Tian-Tian,Miao Miao,Qiu Hui-Ying,Fu Cheng-Cheng,Tang Xiao-Wen,Ruan Chang-Geng,Wu De-Pei,Han Yue

Funder

National Natural Science Foundation of China

Jiangsu Province of China

Jiangsu Provincial Special Program of Medical Science

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-019-03603-3/fulltext.html

Reference40 articles.

1. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy P, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579–585

2. Sierra J, Perez WS, Rozman C et al (2002) Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997–2004

3. Martin PJ, Counts GW Jr, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, Flowers MED, Syrjala KL, Hansen JA, Storb RF, Storer BE (2010) Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 28:1011–1016

4. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socié G (2011) Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 29:2230–2239

5. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, Ljungman P, on behalf of the Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organizat (2016) Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 101:803–811

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epstein–Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada;Current Oncology;2024-05-14

2. The impact of donor and recipient MDR1 G2677TA, C1236T, C3435T match and mismatch on the outcomes of patients after allogeneic hematopoietic stem cell transplantation;2024-03-21

3. Use of Rituximab in Epstein-Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation;J BIOL REG HOMEOS AG;2023

4. The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: A real-world study;Frontiers in Immunology;2022-08-31

5. Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation;Annals of Hematology;2021-06-03